Enhanced protection against nasopharyngeal carriage of Streptococcus pneumoniae elicited by oral multiantigen DNA vaccines delivered in attenuated Salmonella typhimurium

Molecular Biology Reports

Volumn 38, Issue 2, 2011, Pages 1209-1217

  Zhang, Qiao ^a   Ma, Qianli ^a   Li, Qi ^a   Yao, Wei ^a   Wang, Changzheng ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Balanced lethal host vector system; DNA vaccines; Nasopharyngeal carriage; Salmonella typhimurium; Streptococcus pneumoniae

Indexed keywords

BACTERIAL PROTEIN; DNA VACCINE; PNEUMOCOCCAL SURFACE ADHESION A; PNEUMOCOCCAL SURFACE PROTEIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; CELLULAR IMMUNITY; CONTROLLED STUDY; EUKARYOTE; FEMALE; HUMORAL IMMUNITY; MOUSE; MUCOSAL IMMUNITY; NASOPHARYNX; NONHUMAN; PLASMID; PNEUMOCOCCAL INFECTION; PROTECTION; SALMONELLA TYPHIMURIUM; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANIMALS; FEMALE; GENETIC VECTORS; IMMUNE SYSTEM; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NASOPHARYNGEAL DISEASES; PLASMIDS; PNEUMOCOCCAL INFECTIONS; SALMONELLA TYPHIMURIUM; STREPTOCOCCUS MUTANS; STREPTOCOCCUS PNEUMONIAE; VACCINES, DNA;

EUKARYOTA; MUS; SALMONELLA; SALMONELLA TYPHIMURIUM; STREPTOCOCCUS PNEUMONIAE;

EID: 79951580813     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-010-0219-7     Document Type: Article

References (28)

1. D Bogaert R De Groot PW Hermans 2004 Streptococcus pneumoniae colonisation: the key to pneumococcal disease Lancet Infect Dis 4 144 154 1:CAS:528:DC%2BD2cXivVWisrc%3D 10.1016/S1473-3099(04)00938-7 14998500 (Pubitemid 38293138)
2. (2008) 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 83:373-384
3. TA Davies YC Yee K Bush, et al. 2008 Effects of the 7-valent pneumococcal conjugate vaccine on U.S. levofloxacin-resistant Streptococcus pneumoniae Microb Drug Resist 14 187 196 1:CAS:528:DC%2BD1cXhtFWmu73J 10.1089/mdr.2008.0805 18707553
4. HM Lode 2009 Clinical impact of antibiotic-resistant Gram-positive pathogens Clin Microbiol Infect 15 212 217 1:CAS:528:DC%2BD1MXlt1Gitb0%3D 10.1111/j.1469-0691.2009.02738.x 19335368
5. MT Valenzuela C De Quadros 2009 Antibiotic resistance in Latin America: a cause for alarm Vaccine 27 Suppl 3 C25 C28 10.1016/j.vaccine.2009.06.005 19540634
6. EN Miyaji WO Dias M Gamberini, et al. 2001 PsaA (pneumococcal surface adhesin A) and PspA (pneumococcal surface protein A) DNA vaccines induce humoral and cellular immune responses against Streptococcus pneumoniae Vaccine 20 805 812 1:CAS:528:DC%2BD3MXptVSntrk%3D 10.1016/S0264-410X(01)00395-4 11738744 (Pubitemid 34015820)
7. AR Kerr JJ Irvine JJ Search, et al. 2002 Role of inflammatory mediators in resistance and susceptibility to pneumococcal infection Infect Immun 70 1547 1557 1:CAS:528:DC%2BD38XhsFSltrc%3D 10.1128/IAI.70.3.1547-1557.2002 11854243 (Pubitemid 34163434)
8. JB Rubins C Pomeroy 1997 Role of gamma interferon in the pathogenesis of bacteremic pneumococcal pneumonia Infect Immun 65 2975 2977 1:CAS:528: DyaK2sXktVylsbw%3D 9199475 (Pubitemid 27264133)
9. DM Ferreira EN Miyaji ML Oliveira, et al. 2006 DNA vaccines expressing pneumococcal surface protein A (PspA) elicit protection levels comparable to recombinant protein J Med Microbiol 55 375 378 1:CAS:528:DC%2BD28XjslOgsbw%3D 10.1099/jmm.0.46217-0 16533983
10. DM Ferreira M Darrieux ML Oliveira, et al. 2008 Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production Clin Vaccine Immunol 15 499 505 1:CAS:528:DC%2BD1cXkvVGgsLw%3D 10.1128/CVI.00400-07 18184825 (Pubitemid 351967083)
11. JP Lynch III GG Zhanel 2009 Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention Semin Respir Crit Care Med 30 189 209 10.1055/s-0029-1202938 19296419
12. R Malley K Trzcinski A Srivastava, et al. 2005 CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization Proc Natl Acad Sci USA 102 4848 4853 1:CAS:528:DC%2BD2MXjt1Ohs7g%3D 10.1073/pnas. 0501254102 15781870 (Pubitemid 40471542)
13. JA Williams AE Carnes CP Hodgson 2009 Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production Biotechnol Adv 27 353 370 1:CAS:528:DC%2BD1MXmtlKmur4%3D 10.1016/j.biotechadv.2009.02.003 19233255
14. A Knaust M Frosch 2004 Genome-based vaccines Int J Med Microbiol 294 295 301 1:CAS:528:DC%2BD2cXhtVGgu7%2FE 10.1016/j.ijmm.2004.07.008 15532988 (Pubitemid 39381966)
15. DH Barouch 2006 Rational design of gene-based vaccines J Pathol 208 283 289 1:CAS:528:DC%2BD28XhsFKjsro%3D 10.1002/path.1874 16362986 (Pubitemid 43126120)
16. K Nakayama SM Kelly R Curtiss III 1998 Construction of an Asd+ expression-cloning vector: stable maintenance and high level expression of cloned genes in a Salmonella vaccine strain Bio/Technology 6 693 697 10.1038/nbt0688-693
17. JE Galan K Nakayama R Curtiss III 1990 Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains Gene 94 29 35 1:CAS:528:DyaK3MXhslai 10.1016/0378-1119(90)90464-3 2227450 (Pubitemid 20368266)
18. HY Kang J Srinivasan R Curtiss III 2002 Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine Infect Immun 70 1739 1749 1:CAS:528: DC%2BD38Xitl2mtbg%3D 10.1128/IAI.70.4.1739-1749.2002 11895935 (Pubitemid 34242173)
19. DE Briles E Ades JC Paton, et al. 2000 Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae Infect Immun 68 796 800 1:CAS:528:DC%2BD3cXotFOktQ%3D%3D 10.1128/IAI.68.2.796-800.2000 10639448 (Pubitemid 30056538)
20. JR Bosarge JM Watt DO Mcdaniel, et al. 2001 Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae Infect Immun 69 5456 5463 1:CAS:528: DC%2BD3MXmsVaku7c%3D 10.1128/IAI.69.9.5456-5463.2001 11500417 (Pubitemid 32786479)
21. HY Wu A Virolainen B Mathews, et al. 1997 Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult mice Microb Pathog 23 127 137 1:STN:280:DyaK2svivVegtA%3D%3D 10.1006/mpat.1997.0142 9281471 (Pubitemid 27387531)
22. MA Liu 2010 Gene-based vaccines: recent developments Curr Opin Mol Ther 12 86 93 1:CAS:528:DC%2BC3cXnt1Kntro%3D 20140820
23. A Darji S Zur Lage AI Garbe, et al. 2000 Oral delivery of DNA vaccines using attenuated Salmonella typhimurium as carrier FEMS Immunol Med Microbiol 27 341 349 1:CAS:528:DC%2BD3cXhvV2msb4%3D 10.1111/j.1574-695X.2000.tb01448.x 10727890 (Pubitemid 30155829)
24. MF Pasetti EM Barry G Losonsky, et al. 2003 Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats J Virol 77 5209 5217 1:CAS:528:DC%2BD3sXjtFykuro%3D 10.1128/JVI.77.9.5209-5217.2003 12692223 (Pubitemid 36460935)
25. D Qu S Wang W Cai, et al. 2008 Protective effect of a DNA vaccine delivered in attenuated Salmonella typhimurium against Toxoplasma gondii infection in mice Vaccine 26 4541 4548 1:CAS:528:DC%2BD1cXpsValtb0%3D 10.1016/j.vaccine.2008.06.030 18590785
26. R Curtiss III K Nakayama SM Kelly 1989 Recombinant avirulent Salmonella vaccine strains with stable maintenance and high level expression of cloned genes in vivo Immunol Invest 18 583 596 1:CAS:528:DyaL1MXltFaitLk%3D 10.3109/08820138909112265 2659521 (Pubitemid 19120824)
27. S Romero-Steiner T Pilishvili JS Sampson, et al. 2003 Inhibition of pneumococcal adherence to human nasopharyngeal epithelial cells by anti-PsaA antibodies Clin Diagn Lab Immunol 10 246 251 12626450 (Pubitemid 36314448)
28. JC Paton 1998 Novel pneumococcal surface proteins: role in virulence and vaccine potential Trends Microbiol 6 85 87 1:STN:280:DyaK1c3ktlOnug%3D%3D 10.1016/S0966-842X(98)01220-7 9582927 discussion 87-8